Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

In a trial involving 13 pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn, nipocalimab increased the percentage with live birth at 32 weeks’ gestation or later without intrauterine transfusions.

​   The New England Journal of Medicine: Search Results in Pediatrics